Grit Biotechnology
Company Details
Status: Private
Employees: 101-250
Location:
Shanghai, China
Type:
sample
Technology:
sample
sample
sample
About: Grit Bio is a Chinese cell therapy company founded in 2019. The company is developing tumor-infiltrating lymphocyte (TIL) therapy program to address the unmet medical needs and to improve the quality of life for patients with solid tumor.
GT101 - Grit’s non-gene-modified TIL product manufactured using proprietary process - is the first TIL product received Investigational New Drug (IND) approval in China and is currently in Phase 1 clinical trial.
Grit Bio has established three core technology platforms for its TIL development: StaViral® - a retroviral system tailored for TIL engineering, ImmuT Finder® - a high-throughput screening platforms identifying novel T-cell targets, and TIL expansion platform StemTexp® that preferentially enriches TCM and TSCM populations of TIL. The company is currently developing potentially best-in-class gene-engineered TIL therapy based on these platforms.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Grit Biotechnology | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.